Trials / Terminated
TerminatedNCT02080364
Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease
Randomized, Double-blind, Placebo Controlled, Multi-center Registration Trial to Evaluate the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 880 (actual)
- Sponsor
- vTv Therapeutics · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease. Patients will receive either azeliragon or placebo with a patient's participation lasting approximately 18 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Azeliragon | Azeliragon 5mg administered orally, once daily for 18 months |
| DRUG | Placebo | Placebo administered orally, once daily for 18 months |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2018-06-01
- Completion
- 2018-06-01
- First posted
- 2014-03-06
- Last updated
- 2021-05-07
- Results posted
- 2021-05-07
Locations
115 sites across 7 countries: United States, Australia, Canada, Ireland, New Zealand, South Africa, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02080364. Inclusion in this directory is not an endorsement.